宫颈癌组织中LRRC8A、METTL14的表达及临床预后价值  

The expression and clinical prognostic value of LRRC8A and METTL14 in cervical cancer tissue

作　　者：王彩丽[1] 王蕊 张文莉[1] 杨杰 Wang Caili;Wang Rui;Zhang Wenli;Yang Jie(Department of Obstetrics and Gynecology,First Hospital of Yulin City,Shaanxi Province,Yulin 719000,China)

机构地区：[1]榆林市第一医院妇产科,陕西榆林719000

出　　处：《疑难病杂志》2024年第10期1187-1192,共6页Chinese Journal of Difficult and Complicated Cases

基　　金：陕西省卫生健康科研项目(2020E023)。

摘　　要：目的分析宫颈癌(CC)组织中富含亮氨酸重复蛋白8A(LRRC8A)、甲基转移酶样蛋白14(METTL14)的表达,探讨两者的临床意义。方法回顾性选取2019年2月—2021年3月榆林市第一医院妇产科诊治CC术后患者138例的临床资料和病理组织,采用实时荧光定量PCR和免疫组化法检测CC组织中LRRC8A、METTL14 mRNA及蛋白表达;绘制K-M生存曲线,用Log-Rank检验比较曲线的差异;Cox回归模型筛选CC预后影响因素。结果CC癌组织中LRRC8A、METTL14 mRNA表达量高于癌旁组织(t/P=44.520/<0.001,42.352/<0.001),癌组织LRRC8A、METTL14蛋白阳性率高于癌旁组织(χ^(2)/P=124.062/<0.001,107.574/<0.001);FIGO分期ⅠB2~ⅡA期、淋巴结转移患者癌组织LRRC8A、METTL14蛋白阳性率明显高于ⅠA~ⅠB1期及无淋巴结转移患者(LRRC8A:χ^(2)/P=6.338/0.012、4.886/0.027;METTL14:χ^(2)/P=7.547/0.006、10.294/0.001);LRRC8A阳性和阴性组3年总生存率分别为71.43%(70/98)、90.00%(36/40);METTL14阳性和阴性组3年总生存率分别为70.65%(65/92)、89.13%(41/46)。Log-Rank检验结果显示,LRRC8A阳性组、METTL14阳性组3年总生存率分别低于LRRC8A阴性组、METTL14阴性组(Log-Rankχ^(2)=5.065、7.690,P=0.023、0.006);Cox回归分析结果表明,LRRC8A阳性、METTL14阳性、FIGO分期ⅠB2~ⅡA期是影响CC患者生存预后的独立危险因素[OR(95%CI)=1.679(1.301~2.166),1.429(1.156~1.766),1.713(1.187~2.471)]。结论CC组织中LRRC8A、METTL14表达升高,与CC患者FIGO分期、淋巴结转移有关,是评估CC患者不良生存预后的标志物。Objective To analyze the expression of leucine rich repeat protein 8A(LRRC8A)and methyltransferase like protein 14(METTL14)in cervical cancer(CC)and explore their clinical significance.Methods One hundred and thirty-eight patients with CC who underwent diagnosis and treatment from February 2019 to March 2021 were selected.Immunohistochemistry and real-time fluorescence quantitative PCR were used to detect the expression of LRRC8A and METTL14 in CC.K-M survival curve were drew and the differences between the curves were compared by Log Rank test.The prognostic factors affecting CC were screen by COX regression model.Results The expression levels of LRRC8A mRNA and METTL14 mRNA in CC cancer tissues were higher than those in adjacent tissues(t/P=44.520/<0.001,42.352/<0.001).The positive rates of LRRC8A protein and METTL14 protein in cancer tissues were higher than those in adjacent tissues(all P<0.001).The positivity rates of LRRC8A and METTL14 proteins in cancer tissues of patients with FIGO stagingⅠB2-IIA and lymph node metastasis were higher(P<0.05).The 3-year overall survival(OS)of LRRC8A positive and negative groups were 71.43%(70/98)and 90.00%(36/40),respectively;The 3-year OS of METTL14 positive and negative groups were 70.65%(65/92)and 89.13%(41/46),respectively.Log Rank test showed that the overall 3-year survival rate of the LRRC8A positive group and the METTL14 positive group was lower than that of the LRRC8A negative group and the METTL14 negative group,with statistically significant differences(Log Rankχ^(2)=5.065,7.690,P=0.023,0.006).LRRC8A positive and METTL14 positive groups,as well as FIGO staging stages IB2-IIA,were independent risk factors[OR(95%CI)=1.679(1.301-2.166),1.429(1.156-1.766),1.713(1.187-2.471)].Conclusion Elevated expression of LRRC8A and METTL14 in CC are associated with FIGO staging and lymph node metastasis in CC patients,and are biomarkers for signal assessment of poor survival prognosis in CC patients.

关 键 词：宫颈癌 富含亮氨酸重复蛋白8A 甲基转移酶样蛋白14 预后 

分 类 号：R737.33[医药卫生—肿瘤]